[News] Korea’s Next-Gen OLED Push Gains Steam With LG FLiPP, Samsung Wide View Debuts

LG Display reported a first-half 2026 operating profit of 39 billion won despite a 4.3% revenue decline to 11.15 trillion won. Cost reductions and a shift to higher-margin OLED products improved its cost-of-sales ratio to 86.3%. The company completed its exit from large-LCD business and plans further cost cuts.

Zacks Research downgraded LG Display (NYSE:LPL) from Hold to Strong Sell. Weiss Ratings later lowered it from Sell (d-) to Sell (e+). The stock fell 5.8% to open at $3.17. LG Display reported Q1 EPS of -$0.26 on revenue of $3.62B; analysts expect -$0.28 EPS for FY.

LG Display reported Q2 sales of 5.6121 trillion won and an operating loss of 107.7 billion won, citing one-time voluntary retirement costs of about 240 billion won. Excluding these costs, analysts said profitability improved. For H1, sales were 11.1461 trillion won with operating profit of 39 billion won. Securities firms cut target prices after results; iM and SK kept buy ratings.

Chevron (CVX) reported strong Q2 results, but its 20-year power purchase agreement with Microsoft (MSFT) for an AI data center in Texas is seen as more significant. The deal secures long-term revenue for Chevron, insulating it from commodity price volatility, while Microsoft ensures energy supply for its data center.

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

Merck & Co. and Moderna Inc. reported positive late-stage trial results for their mRNA cancer vaccine, intismeran, combined with Keytruda, showing extended time before melanoma recurrence. Moderna's stock more than doubled. Full data pending.